Cytogen gets FDA approval for product licence application (PLA) supplement:
This article was originally published in Clinica
The US FDA has approved Cytogen's PLA supplement for its OncoScint CR/OV, expanding the imaging agent's indications to include readministration to HAMA-negative patients at risk of cancer recurrence. OncoScint received FDA approval in December 1992 and is the only such agent approved for tumour imaging, claims Cytogen. There have been around 150,000 cases of colorectal cancer each year in the US since 1990, according to the American Cancer Society.
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.